184 related articles for article (PubMed ID: 16779706)
1. Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.
White K; Rades T; Kearns P; Toth I; Hook S
Pharm Res; 2006 Jul; 23(7):1473-81. PubMed ID: 16779706
[TBL] [Abstract][Full Text] [Related]
2. Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid-core-peptides.
White K; Kearns P; Toth I; Hook S
Immunol Cell Biol; 2004 Oct; 82(5):517-22. PubMed ID: 15479437
[TBL] [Abstract][Full Text] [Related]
3. Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes.
Demana PH; Fehske C; White K; Rades T; Hook S
Immunol Cell Biol; 2004 Oct; 82(5):547-54. PubMed ID: 15479441
[TBL] [Abstract][Full Text] [Related]
4. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells.
Lipford GB; Wagner H; Heeg K
Vaccine; 1994 Jan; 12(1):73-80. PubMed ID: 8303944
[TBL] [Abstract][Full Text] [Related]
6. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
7. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
8. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol.
Myschik J; McBurney WT; Rades T; Hook S
Int J Pharm; 2008 Nov; 363(1-2):91-8. PubMed ID: 18692555
[TBL] [Abstract][Full Text] [Related]
10. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake.
Cibulski SP; Mourglia-Ettlin G; Teixeira TF; Quirici L; Roehe PM; Ferreira F; Silveira F
Vaccine; 2016 Feb; 34(9):1162-71. PubMed ID: 26826546
[TBL] [Abstract][Full Text] [Related]
11. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
12. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
14. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
[TBL] [Abstract][Full Text] [Related]
15. The immunodominant peptide from listeriolysin in Quil A liposomes vaccinates CD8+ cytolytic T cells and confers protection to infection.
Lipford GB; Lehn N; Bauer S; Heeg K; Wagner H
Immunol Lett; 1994 May; 40(2):101-4. PubMed ID: 8088867
[TBL] [Abstract][Full Text] [Related]
16. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.
Silla S; Fallarino F; Boon T; Uyttenhove C
Eur Cytokine Netw; 1999 Jun; 10(2):181-90. PubMed ID: 10400824
[TBL] [Abstract][Full Text] [Related]
17. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
Franke ED; Corradin G; Hoffman SL
J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
[TBL] [Abstract][Full Text] [Related]
19. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.
Ghochikyan A; Mkrtichyan M; Petrushina I; Movsesyan N; Karapetyan A; Cribbs DH; Agadjanyan MG
Vaccine; 2006 Mar; 24(13):2275-82. PubMed ID: 16368167
[TBL] [Abstract][Full Text] [Related]
20. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
